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Dear Prof. Zanchetti, 
Thank you for your letter of August 1st concerning the manuscript “Endothelial Factors in 
The Pathogenesis and Treatment of Chronic Kidney Disease Part II: Role in Disease Conditions. A 
Joint Consensus Statement from the ESH Working Group on Endothelin and Endothelial Factors 
And The Japanese Society of Hypertension” (JH-D-17-00736). 
We valued much the Reviewers’ constructive criticisms and implemented all suggested 
changes. To ease their tracking in the revised version the changes made are highlighted in yellow 
in the text.  We believe that after this revision the manuscript has been improved considerably 
and can therefore receive a positive evaluation in the present form. 
Therefore, on behalf of my coworkers, I would like to submit the revised version of for 
consideration for publication in Journal of Hypertension.  
We are grateful for the additional consideration to our work and remain your sincerely. 
 
Kindest regards, 
 
Gian Paolo Rossi, FAHA, FACC 
Clinica dell’Ipertensione  
Department of Medicine – DIMED 
University Hospital 
35128 Padova, Italy 
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JH-D-17-00736, "Endothelial Factors in The Pathogenesis and Treatment of Chronic Kidney Disease Part II: 
Role in Disease Conditions. A Joint Consensus Statement from the ESH Working Group on Endothelin and 
Endothelial Factors And The Japanese Society of Hypertension" 
 
 
 
Reviewer #1: 
This is the second part of a large review on endothelial function in relationship to kidney diseases. In general 
this review is fairly well well-written. The weakness is the unsystematic nature of this multi-author effort. I 
have the following comments/suggestions for the authors: 
 
1. The lack of focus on endothelial function as related to the GFR and proteinuria in hypertension is a miss. 
Animal models implicate vascular dysfunction in renal damage in hypertension (reviewed in Am J Physiol 
Regul Integr Comp Physiol. 2009; 296:R1001-18) an alteration likely contributing to the age-dependent 
acceleration of renal function loss in this population. Furthermore, studies showing that nitric oxide synthase 
activity is a major determinant of glomerular haemodynamics in humans (J Hypertension 26:110-116, 2008) 
and descriptive studies in essential hypertension linking endothelial dysfunction as measured by state of art 
techniques and the GFR (Circulation 110:821-5; 2004) exist. 
 
RE: We thank the Referee for the constructive criticisms that helped us in the revision of the manuscript.  
In the revised Introduction we have now clarified that endothelial dysfunction induces renal hemodynamic 
changes, which favour development of CKD and the age-dependent acceleration of renal function loss in the 
hypertensive population.  Moreover, we reported that proteinuria, the marker of renal microvasculature 
damage, invariably associates with systemic endothelial dysfunction in hypertension, suggesting a general 
involvement of endothelium.  
The two references (Am J Physiol Regul Integr Comp Physiol. 2009 and Circulation 2004) have been quoted 
in Part 2, whereas the reference on nitric oxide synthase (JH 2008), being related to the mechanisms, was 
added in Part 1. 
 
 
2. Some sections fail to quote and discuss relevant papers. For example, in the part dedicated to the usefulness 
of ACEi in obesity-related CKD, the authors miss a not so old paper showing that the nephro-protective effect 
of Ramipril in patients with proteinuric CKD is almost confined to overweight and obese patients 
(JASN;22:1122-8; 2011). 
 
RE: A comment on the usefulness of ACEi in the obesity nephropathy was added, and the reference has been 
quoted.  
 
 
3. The part dealing with endothelial factors in kidney transplantation misses several papers related with 
factors implicated in the evolution of endothelial function after transplantation, e.g. ADMA (Transplantation. 
2005;80:1660-6), biomarkers of mineral disorders (Am J Nephrol. 2013;37:126-34). 
 
RE: The involvement of ADMA and FGF23, and the related references, were added to the text. 
 
 
4. In the section "Vitamin D, endothelial function, and kidney protection" there is no focus on FGF23, a bone 
hormone which is probably the most investigated risk factor for cardiovascular disease in CKD. In this respect, 
experimental studies in vitro and in animal models (Am J Physiol Endocrinol Metab. 2014 Sep 1;307:E426-36.; 
PLoS One. 2014;9:e93423 ) and cross-sectional (Kidney Int. 2010;78:679-85) and intervention studies 
investigating the link between FGF23 and vascular function in CKD exist (Am J Kidney Dis. 2012;59:177-85). 
 
Reply to Reviewers
RE: Following your suggestion, we added information on the role of FGF23 and mentioned the RCT in stage 
4 CKD patients. The references were quoted. 
 
 
Reviewer #2: 
In this second part of the review on the role of endothelial factors in the pathogenesis of renal diseases, the 
authors discuss the potential role of the endothelium and its dysfunction in several circumstances of renal 
diseases such as diabetes nephropathy, obesity, pregnancy, cancer therapy, vitamine deficiency and 
transplantation. The authors convincingly demonstrate that the contribution of endothelial dysfunction is 
almost always present in these renal diseases but whether it represents a primary or a secondary event is not 
always clear and the effect of interventions is so far rather scarce in most situations. 
 
RE: We thank the Referee for his/her comments and criticisms, which helped us in the revision of the 
manuscript. The lack of clear evidences mostly derives from the lack of large RCTs designed to test the effects 
of drugs on specific disease-associated CKD.  Hence, whether endothelial dysfunction is a primary or a 
secondary event remains largely known in most conditions. We hope that our review could stimulate RCTs 
in this field. 
 
Comments: 
1. Compared to the first part of the review this second part is less well elaborated and sometimes a bit 
superficial just aligning more or less convincing studies. The authors do not always make it clear that 
interventional results are only obtained in animal models (for ex in transplantation) and that so far, there is 
no clear evidence from clinical trials that any interventions focused on endothelial function (if possible) are 
really effective in most of the clinical situations described in the review. Thus authors should be more clear on 
the level acquired so far in each pathology: this could perhaps be included in a table. At this stage no 
recommendations can be made for clinicians. 
 
RE: We agree that many findings were obtained from experimental studies and RCTs were too small to make 
recommendations. This was true particularly for transplantation-associated hypertension and hence we 
added a note at the end of the section. Moreover, we distinguished the studies on humans from those 
performed in experimental models. 
 
 
2. It should also be mentioned that it is often difficult to disantangle with actual drugs the respective role of 
pathogenic factors such as high BP, AGES, ROS and so on, as interfering on one parameter affects the others. 
 
RE: We added a comment on the difficulties of identifying the role of each pathogenic factor on endothelial 
dysfunction in the Conclusions. 
 
 
3. On page 6 when the authors say that the effects of RAS blockade is largely independent of BP, this is 
partially true. Indeed, what is the evidence that these agents protect the kidney when no change in BP occurs? 
This is why authors talk about effects beyond BP. 
RE: Thank you for this suggestion. We added a comment on this issue and quoted Micro-HOPE, Renaal, IRMA-
2 and IDNT studies.  
 
 
Minor: relevant figures could be added to illustrate the potential role of endothelial dysfunction in some of 
the described diseases. 
RE: An additional figure illustrating the stages of diabetic nephropathy was added (Figure 1). 
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After examining in Part I the general mechanisms of endothelial dysfunction in the kidney vasculature, the 
Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension and the 
Japanese Society of Hypertension herein review current knowledge on the role of endothelial dysfunction 
in multiple disease conditions that affect the kidney.  The few randomized controlled clinical trials 
specifically designed to evaluate strategies for correcting endothelial dysfunction in patients with 
hypertension and/or chronic kidney disease are also discussed alongside their cardiovascular and renal 
outcomes.  
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Abstract 
After examining in Part I the general mechanisms of endothelial dysfunction in the kidney vasculature, the 
Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension and the 
Japanese Society of Hypertension will herein review current knowledge on the role of endothelial 
dysfunction in multiple disease conditions that affect the kidney, including diabetes mellitus, 
preeclampsia, kidney transplantation, hyperhomocysteinemia and cancer treated with anti-angiogenic 
therapy.  The few available randomized controlled clinical trials specifically designed to evaluate strategies 
for correcting endothelial dysfunction in patients with hypertension and/or chronic kidney disease are 
also discussed alongside their cardiovascular and renal outcomes.  
 
Key Words: diabetes mellitus; endothelin; endothelium; hypertension; kidney; diabetes mellitus; 
preeclampsia; kidney transplantation; hyperhomocysteinemia; cancer. 
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1. Introduction 
Impaired endothelium-dependent vasodilation, a hallmark of arterial hypertension and many other 
cardiovascular (CV) disease risk factors and conditions, can be an early mechanism leading to CV damage 
or, alternatively, a marker of it.  Endothelial dysfunction in glomeruli and peritubular vessels affects 
filtration fraction, resulting in a progressive reduction in the glomerular filtration rate (GFR), extracellular 
fluid volume expansion, abnormal ion balance and renal hypoxia, all of which ultimately contribute to the 
age-dependent renal function loss in the hypertensive population and can to chronic kidney disease (CKD) 
[1]. Proteinuria, a marker of renal microvasculature damage, is invariably associated with systemic 
endothelial dysfunction in hypertension, suggesting a general involvement of endothelium [2].  
After examining in Part I the general mechanisms underlying endothelial dysfunction in the kidney, using 
the same methodology, the Working Group on Endothelin and Endothelial Factors of the European 
Society of Hypertension in conjunction with the Japanese Society of Hypertension will herein review 
current knowledge on the role of endothelial dysfunction in conditions where the renal vasculature is 
deeply affected, as diabetes mellitus, preeclampsia, kidney transplantation, hyperhomocysteinemia and 
cancer.  The few randomized controlled clinical trials that explored the concept that strategies aimed at 
correcting endothelial dysfunction in patients with hypertension and/or chronic kidney disease are also 
discussed alongside their cardiovascular and renal outcomes.  
2. Diabetic nephropathy 
Diabetic nephropathy, one of the main preventable causes of reno-parenchymal hypertension and CKD, is 
characterized by focal and segmental glomerulosclerosis [3], which involves multiple factors including 
progressive podocyte injury, glomerular fibrosis, and loss of glomerular filtration function [4,5], leading to 
proteinuria, and ultimately to the need for renal replacement therapy [4](Fig. 1).  Proteinuric CKD, and 
particularly end-stage renal disease (ESRD), not only aggravates hypertension and CV risk [6], but also 
poses an economic rapidly growing burden to society [4], making prevention of this disease a critical  task 
for the future.  
The pathogenesis of diabetic nephropathy not only involves hyperglycemia and inflammation, but also 
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endothelial and non-endothelial pathways [7,8], including enhanced oxidative stress, renin-angiotensin-
aldosterone system (RAAS) and endothelin-1 (ET-1) activation, and inflammatory processes, as discussed 
in Part I [4].  
Obesity, which is frequently associated with insulin resistance and/or diabetes, also leads to focal and 
segmental glomerulosclerosis, a condition termed "obesity nephropathy".  Of note, practically all of the 
aforementioned endothelial mediators of CKD are also implicated in the pathogenesis of diabetic 
nephropathy [9], as they were found to promote and maintain podocyte injury and glomerular and 
vascular inflammation [6,10].  Hence, not unsurprisingly antihypertensive medications targeting 
endothelial pathways, such as angiotensin I converting enzyme (ACE) inhibitors, angiotensin AT1 receptor 
blocker (ARBs) or mineralocorticoid receptor antagonists, have been investigated in diabetic nephropathy, 
as hypertension is common among these patients.  These agents were shown to improve clinical outcome 
with benefit that exceeded that attributable to changes in blood pressure [7,11–14].  Of note, the 
protective effect of ACE inhibitors and ARBs was particularly marked in obesity nephropathy [15] and 
predictably found to be largely blood pressure (BP)-independent [11,13,14], consistent with suggesting 
their direct reno-protective effects [7].  
It has been known for some time that kidney transplantation not only normalizes BP but also reverses 
hypertensive damage in the heart and retinal arteries of patients with proteinuric renal disease and 
hypertension [16], indicating the reversibility of end-organ injury.  Similarly, regression or partial disease 
remission was suggested to occur in patients with diabetic nephropathy treated with ARBs or ACE 
inhibitors, in whom proteinuria decreased [7].  Reversal of diabetic or non-diabetic focal and segmental 
glomerulosclerosis and/or proteinuria has also been observed in studies with ET-1 receptor antagonists, 
both experimentally and clinically [17–19].  Currently, a novel approach to interfere with progression of 
diabetic nephropathy under investigation entails the pharmacological inhibition or downregulation of 
reactive oxygen species (ROS) generating NADPH oxidases (Nox) enzymes [20,21] 
(https://clinicaltrials.gov/ct2/show/NCT02010242).  
Statins have also been shown to inhibit inflammatory activation in both endothelial cells and the 
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vasculature [8], but so far the clinical trials conducted in patients with diabetic nephropathy have failed to 
prove their beneficial effect on the natural history of the disease [6].  
Finally, strategies employing preventative measures, such as weight loss /bariatric treatment of obesity 
[8],  lifestyle changes to improve and maintain cardiorespiratory fitness or pharmacological interventions, 
such as anti-diabetic therapy or those targeting the aforementioned endothelial mediators can 
conceivably reduce BP, delay vascular and renal aging, and thus contribute to an improved overall CV 
outcome [8,22–30]. 
3. Preeclampsia associated kidney injury 
Preeclampsia is the most frequent (prevalence about 3-8%) serious medical complication of pregnancy.  It 
develops through two stages [31,32]: in stage 1, aberrant shallow cytotrophoblast invasion in the 
maternal spiral arteries supplying the placenta results in poor placentation; in stage 2 this leads to 
repeated periods of placental hypoxia and reperfusion injury, resulting in oxidative stress and an 
increased production of placental factors (Fig. 2).  Among the latter, soluble Fms-like tyrosine kinase 1 
(sFlt-1), a splice variant of the membrane-bound vascular VEGF type 1 receptor originating from placental 
synthiotrophoblasts, has been widely studied. Others include soluble endoglin, agonistic auto-antibodies 
to the AT1 receptor, and inflammatory cytokines [33,34].  All these factors, likely in combination with an 
altered immune system in preeclampsia [35,36], are thought to contribute to generalized endothelial 
dysfunction, although their precise roles remain unclear.  For example, in preeclamptic women, both 
circulating sFlt-1 and ET-1 levels rise progressively in relation to the severity of preeclampsia [37,38].  
These factors affect not only growth and development of the placenta and the fetus, but also the health 
of endothelial cells and kidney function, including the maintenance of the glomerular filtration barrier 
[39].  Moreover, elevated sFlt-1 levels, by binding both free VEGF and placental growth factor, disturb the 
balance between pro- and anti-angiogenic factors.  Hence, these mechanisms may contribute to arterial 
hypertension and renal damage in preeclampsia [35]. 
Accordingly, as discussed later, treatment of cancer patients by blocking angiogenesis via VEGF inhibition 
(with tyrosine kinase inhibitors, and direct VEGF inhibition or inactivation) resulted in a preeclampsia-like 
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syndrome, featuring hypertension, proteinuria, and glomerular endotheliosis [40].  Moreover, VEGF 
inhibitor-treated cancer patients, like preeclamptic women, display high ET-1 levels, which correlated 
closely with the degree of VEGF inhibition, as estimated by either the serum sFlt-1 levels or the VEGF 
inhibitor dose [37].   Multiple regression analysis has pointed to a role for ET-1 as an independent 
determinant not only of the BP rise and proteinuria, but also of renin suppression in pre-eclamptic women 
[37].  Therefore, ET-1 activation seems to be involved in causing both the clinical manifestations of 
preeclampsia, and the well-known paradoxical suppression of renin in this disease.  ET-1 additionally acts 
as an aldosterone secretagogue via ETB receptors [41], while auto-antibodies to the Angiotensin II (Ang II) 
type 1 receptor might do the same.  Obviously, these antibodies should also suppress renin release via AT1 
receptor activation. Consequently, theoretically preeclamptic women would be expected to display an 
increased aldosterone/renin ratio, due to the opposite effects of ET-1 and auto-antibodies on renin and 
aldosterone, but, in contrast with this prediction, no such increase was observed [37], suggesting that 
multiple complex mechanisms modulate the effects of ETB receptors and autoantibodies in-vivo.  A 
possible explanation is that the VEGF-induced increase in adrenal capillary density, which in normal 
pregnancy upregulates aldosterone production, is disturbed in preeclampsia because sFlt-1 blocks such 
effects of VEGF [42].  
Animal models of preeclampsia support the importance of sFlt-1/ET-1 upregulation in that ET-1 receptor 
blockade alleviates preeclampsia symptoms, in keeping with the effects seen with these agents in VEGF 
inhibition-induced hypertension [37,43,44].  The cause of the rise of ET-1 in preeclampsia remains to be 
determined. Although acute VEGF inhibition in human umbilical vein endothelial cells did not affect ET-1 
release [45], soluble endoglin has been suggested to induce endothelial ET-1 production [46].  If 
confirmed, this could lead to the development of entirely new treatment targets. ET receptor antagonism, 
having been linked to teratogenicity, might be feasible only at a late pregnancy stage, when all organs 
have been formed.  
4. Kidney transplantation and transplant-associated hypertension 
The global burden of ESRD patients needing renal replacement therapy and transplantation is continuing 
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to rise. This is a huge financial burden to health care systems [47], which will continue to rise with 
improved survival from CV disease in these patients.  Endothelial dysfunction is held to be central to both 
CKD development and the CV continuum as discussed in Part I [48].  Renal transplanted patients are no 
exception to this, which is clearly understandable given that circulating immune response cells find the 
endothelium as the first barrier to their attack on the transplanted organ.  Although advances in the 
treatment of acute rejection and short-term graft survival now allow a 90% survival at 1 year [49], long-
term success has been more difficult to achieve.  Oxidative stress is enhanced in recipients of kidney 
transplants and starts before transplantation during ESRD.  It is then aggravated during the ischemia-
reperfusion occurring with the grafting, and then further exacerbated as a consequence of long-term 
immunosuppressant treatment, more with cyclosporine, which causes hypertension and renal damage, 
than with the newer immunosuppressive drugs like tacrolimus [50].  Moreover, several factors involved in 
the impaired vasorelaxation of transplanted patients, including ET-1 (see below), ADMA, and FGF23 (see 
section on vitamin D) are held to contribute to renal damage [51,52]. 
After hepatic, cardiac, and renal transplantation, circulating levels of ET-1 increase [53–56], indicating 
systemic activation of the ET system and decreased ETB receptor-mediated ET-1 clearance.  Accordingly, 
impaired endothelial cell function associated with ET-1 activation has been observed in human allograft 
recipients [57].  Cyclosporine is not only a potent stimulus for ET-1 production [58], but also an inhibitor of 
the L-arginine /nitric oxide (NO) pathway [59]; thereby, it contributes to post-transplant hypertension 
[60].  Moreover, ETA receptor expression increases in renal allografts [61] and endothelin receptor 
antagonist (ERA) treatment effectively suppresses fibrotic and proliferative responses in several allografts 
[62–70].  Accordingly, selective ETA [71,72], but not mixed ETA/ETB blockade [73], largely prevents chronic 
rejection and renal allograft injury, even in the absence of continued immunosuppression [71] through 
mechanisms not improved by ARB treatment [74], suggesting that ERA have pronounced and independent 
immunomodulatory effects in the transplant recipient [75].  However, findings were mostly obtained in 
experimental models [62–75], while RCTs [53–61] were too small to recommend a specific class of drugs 
to transplant-associated hypertension. 
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5. Angiogenesis antagonists and the renal endothelin system  
Angiogenesis is a key process for tumor growth and metastatic spread.  This has led to the development 
and introduction in the clinic of a large number of agents (such as anti-VEGF antibodies and small, orally 
active receptor tyrosine kinase inhibitors that block the VEGF signaling pathway) aimed at blunting the 
actions of vascular endothelial growth factor.  The latter regulates angiogenesis through endothelial cell 
proliferation and can play an important role in capillary repair in damaged glomeruli [76].  Common 
adverse effects of these agents are hypertension and kidney injury, which resemble the manifestations of 
preeclampsia, where the release of sFlt-1 in the bloodstream, by sequestering VEGF and placenta growth 
factor, is held to produce an antiangiogenic state [77].  As in preeclampsia, activation of the ET system 
occurs in cancer patients treated with the receptor tyrosine kinase inhibitors sunitinib and 
regorasorafenib [45,78].  In pregnant rats the antiangiogenic factor sFlt-1 causes a rise in BP and 
expression of the preproET-1 gene in the renal cortex [79].  Moreover, overexpression of sFlt-1 in mice 
also increases renal expression of preproET-1 and ETA receptor, effects that are amplified in endothelial 
nitric oxide synthase (eNOS)-deficient mice [80].  Thus, inhibition of angiogenesis leads to ET-1 activation, 
particularly when NO bioactivity is blunted.  Accordingly, sunitinib dose-dependently increased plasma ET-
1 levels in rats, but unexpectedly did not increase the urinary excretion of ET-1, a marker of renal ET-1 
production [81].  Moreover, opposite to what seen with sFlt-1 administration in pregnant rats, expression 
of the preproET-1 and endothelin converting enzyme genes were not increased.  Notwithstanding this, the 
mixed ERA macitentan prevented the rise in BP and proteinuria in sunitinib-exposed rats [82], while 
amlodipine, which similarly lowered BP, did not affect proteinuria [82]. 
In summary, even though the effects of sFlt-1 and sunitinib on renal expression of the pre-pro-ET-1 gene 
may not be uniform, it can be concluded that anti-angiogenic treatment activates the ET-system and that 
data with ERA treatment support a role of the ET-system in the development of proteinuria following 
antiangiogenic treatment. 
6. Hyperhomocysteinemia, endothelial dysfunction and renal damage   
Hyperhomocysteinemia defined as a total plasma homocysteinemia > 15 mol/L, affects 5-7% of the 
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general population and 20-40% of those with coronary atherosclerosis [83,84].  It usually derives from a 
gene-environment interaction involving a low folate intake and the presence of variants of the methylene-
tetra-hydro-folatereductase (MTHFR) gene (ID 4524), particularly in elderly people and in the presence of 
reduced eGFR [85,86].  Two non-synonymous single nucleotide polymorphisms for the MTHFR gene have 
been described: C677T in exon 4 (Ala222Val) that results in a MTHFR variant with decreased stability to 
temperature (thermolabile variant), and an A1298C (Glu429Ala) in exon 7 that impairs MTHFR activity to a 
lesser extent than C677T [87].  These variants, in the presence of a low folate supply, lead to  
hyperhomocysteinemia, which detrimentally affects the endothelium by inducing oxidative stress, with 
ensuing decreased NO production and NO bioactivity [88], and also accumulation of the endogenous NO 
synthase inhibitor asymmetric dimethylarginine (ADMA) [89].   
Declining renal function, alongside aging and left ventricular systolic dysfunction, are recognized factors 
associated with hyperhomocysteinemia.  ESRD patients are expected to develop hyperhomocysteinemia, 
because the kidney is the major site of homocysteine metabolism and, moreover, dialysis is associated 
with loss of water-soluble B vitamins, which are key for maintaining normal plasma homocysteine levels 
[90].  Hyperhomocysteinemia induces severe oxidative stress, thus leading to oxidation of free or protein-
bound thiols and aggravation of endothelial dysfunction [90,91].  Accordingly, the MTHFR gene variants 
have been linked to kidney damage: the C677T variant was found to be associated with CKD in both the 
cross-sectional Japan Multi-institutional Collaborative Cohort (J-MICC) Study [92] and with mortality risk in 
ESRD patients of the Homocysteinemia in Kidney and End Stage Renal Disease (HOST)-DNA study [93].  An 
association was also found between the decline of GFR and A1298C variant in the longitudinal African-
Americans Study of Kidney Disease and Hypertension (AASK) Trial [94]. 
A recent Cochrane analysis of 6 studies on the effects of folic acid or vitamins B6 and vitamin B12 in ESRD 
patients, however, failed to show a decrease in CV events and/or death, leading the contention that 
homocysteine-lowering therapies should not be used for CV risk reduction [95].  This conclusion, however, 
cannot be taken for granted for the following reason.  Since there is a linear relationship between plasma 
homocysteine and CV risk events over the entire range of plasma homocysteine values, a benefit from 
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lowering homocysteine may be expected only in those who have overt hyperhomocysteinemia before 
they develop ESRD [84] and not in the population at large where the beneficial effect seen in a subset of 
the subjects can be markedly diluted.  In keeping with this prediction a recent large study in patients with 
mild-to-moderate CKD found that the combined treatment with enalapril and folic acid supplementation 
delayed the progression of CKD, as compared to enalapril alone [96].  The concept that lowering plasma 
hyperhomocysteinemia is beneficial is further supported by evidence that folic acid supplementation 
protected from CVD patients with low folic acid levels and without preexisting CV disease [97]. 
7. Endothelial factors, kidney protection, and disease prevention 
In this era of evidence-based medicine randomized controlled clinical trials (RCTs) are the basis for high 
level evidence and Class I recommendations.  Whether specifically targeting endothelial dysfunction may 
ultimately improve CV and renal outcomes in hypertension and CKD patients remains to be demonstrated 
in adequately designed, long-term RCTs.  As a proof-of-principle, a study that used a remote ischemic 
preconditioning strategy to improve endothelial function reported prevention of acute kidney injury in 
high-risk patients undergoing cardiac surgery (mean eGFR 56 ml/min/1.73 m2)[98], thus supporting the 
contention that endothelial factors may be targets for kidney protection in humans [99].  
We suggest that a holistic approach to treat hypertension, hyperlipidemia, and diabetes mellitus 
(with/without diabetic nephropathy) should be the optimal strategy to prevent CKD, or at least retard its 
progression.  However, studies involving specific targets suggests the possibility of achieving additional 
benefits.  For example, in four small trials the addition of spironolactone for 60 days, on top of RAAS 
inhibition, improved microalbuminuria, and decreased BP and eGFR, without altering plasma biomarker 
concentrations of endothelial dysfunction [100].  Aldosterone breakthrough may occur in patients with 
diabetic nephropathy treated with an ACE inhibitor or an ARB, likely because the secretion of aldosterone 
is controlled by multiple mechanisms, besides Ang II [101,102].  Notably, aldosterone breakthrough has 
been associated with enhanced microalbuminuria [103], which might explain why low dose 
spironolactone (25 mg daily) on top of standard antihypertensive treatment reduced microalbuminuria 
despite no significant BP changes [104].  Moreover, spironolactone induced a sustained antiproteinuric 
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effect when added on top of an ACE inhibitor or an ARB in a longer (1-year) study [103].  Similarly, in a 
larger RCT, eplerenone (50 to 200 mg daily) was more effective in reducing microalbuminuria than 
amlodipine in spite of similar lowering BP and pulse pressure in patients with systolic hypertension [105].   
In CKD patients the use of mineralocorticoid receptor antagonists, especially if combined with ACE 
inhibitors and/or ARBs, has been limited by the fear of hyperkalemia [106,107].  However, serious 
hyperkalaemia developed in less than 1% of the patients with non-diabetic I-III CKD stages (eGFR 30-89 
mL/min/1.73m2) receiving 25 mg spironolactone on top of ARB or ACE inhibition, whereas a significant 
decrease in urinary albumin excretion greater or equal to 50% was observed in 35% of the patients [108].  
Nonetheless, even though in most cases mineralocorticoid receptor antagonists are effective and safe 
[109], caution should be exercised in prescribing these agents to CKD patients with an eGFR< 45 
mL/min/1.73m2 and serum K+ levels > 4.5 mmol/L on appropriately dosed diuretic treatment, as these 
features predict the development of hyperkalemia. 
Several small-sized short-term RCTs were performed to target the molecular pathways involved in 
endothelial dysfunction in CKD and hypertension [110–114].  In an attempt to improve the endothelial 
function with an antioxidant therapy, a double-blind pilot RCT was performed in nine CKD patients with 
stable chronic heart failure, treated with placebo or N-acetylcysteine (500 mg orally twice daily) for 28 
days followed by a wash-out period (>7 days) and cross-over to the other treatment.  This study showed 
that N-acetylcysteine therapy was associated with improved forearm blood flow after ischemia caused by 
suprasystolic pressure of 200 mmHg [110]. 
Cilostazol, a phosphodiesterase inhibitor with antiplatelet/antithrombotic effects, used in chronic 
peripheral arterial disease, induces vasodilatation and inhibits vascular smooth muscle cells proliferation 
[111].  In a small single-blinded study, patients with peripheral arterial disease and diabetic nephropathy 
(baseline eGFR of 73 (placebo)-77 (cilostazol) ml/min/1.73 m2) were randomized to oral cilostazol (100 mg 
b.i.d.) or placebo for one year.  Microalbuminuria and albumin-creatinine ratio were significantly reduced 
in the cilostazol group as compared to the placebo group, alongside a decrease in the plasma 
concentration of endothelial (leukocyte adhesion molecules) markers E-selectin and vascular cell adhesion 
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molecule-1 (VCAM-1), but no changes in BP or eGFR [111]. 
Phosphodiesterase type 5 (PDE5), expressed in the endothelial, glomerular, mesangial, cortical tubular, 
and inner medullary collecting duct cells, degrades cGMP, and experimental data suggest that PDE5 
inhibitors can be useful in preventing CKD.  Sildenafil, one PDE5 inhibitor, prevented glomerular 
hypertension and hyperfiltration in rats with subtotal nephrectomy [115,116], and reduced protein 
excretion in streptozotocin-induced diabetes [117]; it also improved flow-mediated vasodilation in 
diabetic men [118,119].  Vardenafil, another PDE5 inhibitor, also reduced proteinuria in rat streptozocin-
induced type 1 diabetes mellitus, and restored nephrin and podocin expression in podocytes [120].  
Whether these agents help in mantaining the kidney function remains to be tested in long-term RCTs.   
ADMA is a by-product of the methylation of arginine residues, which acts as a competitive inhibitor of L-
arginine to reduce NO production, and also causes decoupling of eNOS leading to ROS production instead 
of NO [121].  The circulating levels of ADMA are increased in CKD in proportion to the severity of renal 
impairment and predict cardiovascular outcomes [122]. Oxidative stress also increases ADMA 
concentration by upregulating the synthetic enzyme protein arginine methyltransferase-1 (PRMT-1) and 
downregulating dimethylarginine dimethylaminohydrolase (DDAH), the enzyme degradating ADMA [123].  
Vitamin E supplementation and (transiently) intravenous ascorbic acid level reduce ADMA levels in 
patients with CKD [124], suggesting that this may represent an important mechanism by which 
antioxidants exert a beneficial cardiovascular effect. 
High uric acid levels promote oxidative stress and might induce endothelial dysfunction.  However, few 
studies that investigated if allopurinol could restore endothelial function in hyperuricemic patients, have 
given quite heterogeneous results, with some suggesting a benefit and others no effect [112,125,126].  
8. Vitamin D, endothelial function, and kidney protection 
As endothelial cells not only express the vitamin D receptor, but also respond to calcitriol, the active form 
of vitamin D, a placebo-controlled RCT investigated the effect of a 12-week treatment with calcitriol on 
endothelial function in patients with stage 3-4 CKD [127].  
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The vitamin D receptor activator paricalcitolat, given at a dose (2 μg/d) that did not affect endothelium-
independent vasodilation and BP, improved endothelium-dependent vasodilation, and slightly lowered 
eGFR (−3.2 mL/min per 1.73 m2 (−4.9 to −1.4), P<0.001), two changes that disappeared after drug 
withdrawal [127].  Interestingly, the beneficial effect of paricalcitol was maximal in patients with no or 
minimal changes in serum phosphate levels and was abolished in patients with hyperphosphatemia.  
Hence, the endothelium-protective effect of vitamin D receptor activation might be potentiated by 
phosphate lowering interventions [113].  
Another RCT using placebo, 1 or 2 μg of paricalcitol daily for 3 months in 36 non-diabetic CKD patients 
(mean eGFR 40 ml/min/1.73 m2) reported a decline in endothelial function, which occurred in the group 
receiving the highest dose of paricalcitol, with no changes in BP, eGFR and microalbuminuria [128].  By 
contrast, in a double-blind, placebo-controlled RCT conducted in patients with type 2 diabetes and stage 3 
or 4 CKD, paricalcitol 1 μg daily had no effect on endothelial function, measured by brachial artery flow-
mediated dilation, or plasma biomarkers of inflammation and oxidative stress. A smaller RCT performed 
with oral ergocalciferol, or placebo, over 6 months, in patients with non-diabetic CKD stage 3–4 and 
concomitant vitamin D deficiency, showed that a high dose ergocalciferol therapy improved 
microcirculatory function and reduced oxidative stress, without altering BP, eGFR or albuminuria [129].  
In a small RCT phosphate lowering treatment with sevelamer improved flow-mediated vasodilatation and 
fibroblast growth factor 23 (FGF23) levels, alongside flow-mediated vasodilatation [130]. FGF23 is a 
hormone regulating serum phosphate and vitamin D, whose plasma levels are markedly elevated in 
patients with CKD [130].  The findings of the RCT, along with the evidence that FGF23 impairs 
vasorelaxation by decreasing NO bioavailability [131], suggest that FGF-23 contributes to vascular 
dysfunction in patients with stage 4 CKD and, therefore could be a target for pharmacologic intervention.  
However, larger and longer intervention studies are necessary to establish a protective effect of vitamin D 
and/or other factors affecting calcium/phosphate metabolism on the kidney.  
9. Conclusions and recommendations 
Diabetes mellitus, preeclampsia, kidney transplantation, hyperhomocysteinemia and anti-angiogenic 
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therapy are all factors that deeply affect endothelial function favouring the development of kidney 
damage and amplifying injury primarily induced by metabolic abnormalities.  As in all diseases a better 
understanding of the underlying mechanisms will improve prevention and treatment of kidney disease.  
However, so far translation of new generated knowledge into clinical practice has been slow with current 
pharmacologic tools, likely because of the difficulty of disentangling the relative role of each putative 
pathogenic factor.  Hence, further specific research is needed particularly in the field of RCTs focused at 
testing strategies for preserving endothelial function and GFR.  To this end this Working Group welcomes 
and supports the planning of integrated research efforts from all investigators who share an interest for 
the endothelium and preservation of renal health. 
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Legends to the Figure 
Figure 1.  Stages of diabetic nephropathy. A. Structure of glomerulus and tubulus under normal 
conditions.  B. At an early stage, the high glucose levels cause andothelial injury and, via hyperinsulinemia 
and release of growth factors, also mesangial expansion and glomerular hypertrophy. Vasoconstriction of 
the efferent arteriole, mostly induced by angiotensin II and aldosterone, causes hyperfiltration. C. With 
time, angiotensin II, aldosterone and endothelin-1 further worsen the endothelial function and induce 
podocyte loss, causing microalbuminuria and decreased filtration.  They also induce endothelial-to-
mesenchymal transition (EndMT) and fibrosis.  D. Glomerular and tubulointerstitial fibrosis, by provoking 
glomerular shrinkage and preventing comunications between endothelial and tubular cells, cause further 
reduction of filtration and protein loss. 
Figure 2. Endothelial dysfunction and abnormal placentation in preeclampsia. During normal 
placentation, cytotrophoblast cells invade the maternal decidual arteries, remodeling them into high 
capacitance vessels that supply the placenta and fetus with maternal oxygen and nutrients.  In 
preeclampsia, this process is aberrant.  The invasion of the trophoblasts is incomplete, with 
cytotrophoblast cells only in the superficial layers of the decidua, and the spiral arteries maintain features 
of high resistance vessels (stage 1).  Shallow trophoblasts invasion leads to placental hypoxia and 
reperfusion injury, with increased oxidative stress and production of placental factors, mainly sFlt-1 (stage 
II).  sFlt-1,  combined to soluble endoglin, agonistic auto-antibodies to the AT1 receptor and inflammatory 
cytokines causes endothelial dysfunction, finally leading to arterial hypertension and kidney damage in 
the mother and growth retardation in the fetus. 
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